Search PubMed⌕ Search

Biomedical subjects

A Goudeau

Publications and source records attributed to A Goudeau.

At least 109 records · Page 6Linked to original sources
PubMed1988

[Serologic diagnosis and epidemiology of acute delta hepatitis in Indre-et-Loire].

A 6 years retrospective study (1981-1986) of 153 consecutive cases of HBsAg positive acute hepatitis was carried out to assess the prevalence of delta virus infections in the Indre-et-Loire a district of the Loire Valley in France. Diagnostic value of the various serum markers of delta infection, i. e. HDAg, anti-HD and anti-HD IgM, were evaluated using immunoenzyme assays. During the survey, 22 cases of delta hepatitis were diagnosed (12 co-infections, 10 superinfections). They all involved young adults, 21 of them were drug-addicts, and one young woman was the consort of a drug-addict. In Indre-et-Loire, delta virus infection was responsible for half of acute HBsAg positive hepatitis among drug-users in the last 3 years of our study. Clinical and biological features of acute delta hepatitis were compared to those of the other HBsAg positive hepatitis: two cases of fulminant hepatitis occurred among the 12 co-infections; 4 of 6 superinfection that could be followed up to 6 months developed biopsy-proven chronic active hepatitis. Delta Ag was found constantly during the first week of the disease, its disappearance was always followed by a seroconversion to anti-HD after four weeks. Anti-delta IgM was an inconstant and late marker: it was detected within the first 4 weeks in only one case (a co-infection); it persisted only in superinfections. Our study shows that delta Ag is an efficient serum marker for the early diagnosis of acute delta hepatitis.

Acute Disease↗
PubMed1987

[Delta hepatitis].

Hepatitis delta virus is a small defective RNA virus that replicates only in the presence of hepatitis B virus. Delta infections occur in two circumstances: co-infections where both viruses are acquired simultaneously, and superinfections where delta virus infects a patient who is already a chronic carrier of hepatitis B virus. In both cases, delta virus may induce a more severe outcome of the disease. Diagnostic tests of delta infection have recently become available and should be used in all cases of acute hepatitis B occurring in populations at risk of delta infection such as intravenous-drug addicts. Prevention of delta infection is essentially based on immunization against hepatitis B of populations exposed to both viruses.

Hepatitis Antibodies↗
PubMed1987

[Maternal-fetal Haemophilus influenzae infections].

In a systematic screening programme for neonatal infections involving 16,008 births, Haemophilus influenzae was isolated in 14 mother-infant couples (0.8 to 1,000 births). Comparisons with other series published in the U.S.A. showed similar circumstances of occurrence and initial clinical manifestations. However, the course of the infection was different, since there was no septicaemia or meningitis in our series. This raises the question of whether the strains responsible for the disease in the U.S.A. have a particular aggressiveness that is unidentifiable by serotype or biotype. In view of the post-partum occurrence of pelvic infections after isolation of H. influenzae during high risk deliveries, asymptomatic parturient women should be treated prophylactically. The 14 strains of H. influenzae isolated, most of them non capsulated and 2/3 of them of biotype IV, probably were of genital origin, although there was no evidence of cervico-vaginal infection. These results are consistent with the concept of genitotropic H. influenzae.

Female↗
PubMed1987

[Gastrointestinal infections in children. A strategy for searching pathogenic agents].

From a bacteriological and virological study of 2056 stool samples obtained from 1595 children we have attempted to derive epidemiological arguments leading to an algorithm of coprodiagnosis. We believe that Rotavirus should be systematically searched for at any age, as it is the most frequent pathogen encountered (27% of children with positive detection). If the test is positive, no other test needs to be performed in patients staying less than 4 days in hospital. If the test is negative, or if the child's clinical condition requires prolonged hospitalization, conventional bacteriology must be carried out, including a search for Salmonella, Shigella and Yersinia. The search for Campylobacter should be limited to infections occurring in children under five.

Adolescent↗
PubMed1987

Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast.

Serological investigations in the Ivory Coast indicate that, despite the rarity of overt acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) is widely prevalent. So also is human T-lymphotropic virus type IV (HTLV-IV). The highest rates of HIV and HTLV-IV seropositivity were observed in female prostitutes. These findings suggest that, like HIV, HTLV-IV can be transmitted by heterosexual contact, and that the mobility of prostitutes may be an important factor in spread of the retroviruses in Africa. The incidence of HIV-associated AIDS in the Ivory Coast is likely to rise sharply in the next few years.

Acquired Immunodeficiency Syndrome↗
PubMed1987

Non-A, non-B fulminant viral hepatitis in France in returnees from Asia and Africa.

Among 61 patients admitted for non-A, non-B fulminant viral hepatitis to Hôpital Beaujon, 10 had returned from Asia or Africa, and 51 had not been outside France, within the month preceding jaundice. This suggests that hepatitis might have been contracted in Asia or Africa in the former, and in France in the latter. The interval between the onset of jaundice and the onset of hepatic encephalopathy was 10 days in the former and 26 days in the latter (P less than 0.03). The serum of the patient returning from Asia contained, and the sera of the nine patients returning from Africa did not contain, antibodies to a virus isolated from the stools of patients suffering from an epidemic fecal-oral non-A, non-B viral hepatitis in Central Asia. It is concluded that infection with Asian-African non-A, non-B viruses can be the cause of fulminant hepatitis in persons returning from these countries, that the course of this type of non-A, non-B fulminant viral hepatitis is shorter than that of non-A, non-B fulminant hepatitis contracted in France, and that different viruses might be responsible for non-A, non-B hepatitis in Asia and Africa.

Adult↗
PubMed1987

Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers.

In a comparative study of the immunogenicity of different hepatitis B vaccines, 339 healthy seronegative adults at three different centres were randomly allocated to receive either three doses of a yeast-derived vaccine at one of three different dose levels (10, 20, or 40 micrograms; SmithKline Biologicals) or one of two commercial plasma-derived vaccines at standard dose levels (5 micrograms, Institut Pasteur Production or 20 micrograms, Merck Sharp & Dohme). The subjects were inoculated intramuscularly in the deltoid region according to a 0, 1, and 6 month schedule. No severe or serious adverse reactions attributed to any of the vaccines were observed. One month after the third vaccine dose, seroconversion rates ranged from 95% to 100% in all groups with only 6 subjects failing to seroconvert. Although there were no statistically significant intra-centre differences in antibody levels, the Tours/Chateauroux groups generally attained higher antibody levels than those from Limoges for the same yeast-derived vaccine dose. This unexplained difference between centres was not found for the plasma-derived vaccines. Older subjects responded less well than younger ones and females attained higher antibody levels than did males. The yeast-derived vaccine is comparable to the two commercially available plasma-derived vaccines in terms of reactogenicity and immunogenicity.

Adult↗
PubMed1986

Fulminant viral hepatitis and pregnancy in Algeria and France.

The relationship between fulminant viral hepatitis (FVH) and pregnancy was compared in Algeria and France. This comparison was based on the study of 22 Algerian and 77 French pregnant and non-pregnant women, aged 15 to 49 years, consecutively admitted for FVH to the Centre Hospitalier Universitaire, Constantine, Algeria, or to Hôpital Beaujon, Clichy, France. The observed and expected (calculated from demographic data) percentage of pregnant women was significantly different among the Algerian patients with FVH (45.5% v. 24.9%, P less than 0.03), but not among the French patients (3.9% v. 5.8%). Hepatitis A was the cause of FVH in none of the Algerian patients, but in eight French patients, none of whom was pregnant. Hepatitis B was the cause of FVH in one non-pregnant Algerian patient and in 49 French patients, two of whom (4.1%) were pregnant. Hepatitis non-A, non-B was the cause of FVH in 21 Algerian patients, ten of whom (47.6%, a percentage significantly higher than expected, P less than 0.04) were pregnant, and in 19 French patients, one of whom (5.3%, a percentage similar to that expected) was pregnant. In conclusion, (1) there is a relationship between FVH and pregnancy in Algeria, but not in France, and (2) this difference is mainly or exclusively attributable to infection with a non-A, non-B virus affecting the Algerian population, but which is much less common or absent in France.

Acute Disease↗
PubMed1986

[Infectious viral diarrheas. Comparison of research methods for rotaviruses].

Radioimmunoassay and enzyme immunoassay (EIA) are generally recommended for routine diagnosis of rotavirus infection in childhood gastroenteritis. Expensive and delicate, these techniques are ill-suited for processing a small number of samples. Recently, Latex agglutination tests have been introduced than can be performed by non specialized hospital laboratories. However, some questions have been raised as to the sensitivity and specificity of these tests. We have sought a direct appraisal of latex agglutination testing by comparing two enzyme immunoassays and two latex tests (Rotazyme, Enzygnost-Rotavirus, Rotalex, Slidex Rota-kit). Three comparative studies that involved 1217 stool samples from children with gastroenteritis were carried out. Specificity, sensitivity, of latex tests compared favorably with the more sophisticated EIA, they represent a very convenient alternative for routine laboratory use provided latex tests with low rate of non-specific agglutinations are chosen.

Child↗
PubMed1985

Immunogenicity of hepatitis B vaccine in guinea-pigs, mice and man.

The immunogenicity of the hepatitis B vaccine Hevac B Pasteur was assayed in guinea-pigs. The reproducibility of the test was determined by comparing the ImD50 of two samples of vaccine in 12 and eight groups of 40 animals each. The variation coefficient between groups was approximately 30%, similar to that found for other vaccines assayed in biological tests in vivo. The sensitivity of the test was determined by comparing the dose response curves in mice, guinea-pigs and humans. The results showed that one ImD50 in man (after one injection) was approximately equivalent to 3 ImD50 in guinea pigs and to 100 ImD50 in Balb/C mice. Stability of Hevac B at 37 degrees C was assayed by determining in guinea-pigs the ImD50 of a series of samples of vaccine that had been incubated at 37 degrees C for varying amounts of time. The immunogenicity of the vaccine was found to decay with a half-life of ten to 15 days at 37 degrees C.

Adult↗
PubMed1985

Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers.

Infants born to carrier mothers positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) received 5 micrograms of hepatitis B virus (HBV) vaccine on four occasions. Group 1 received vaccine only, group 2 received vaccine plus hepatitis B immune globulin (HBIG) at birth, and group 3 received vaccine plus HBIG at birth and at one month. Infants born to HBeAg-positive mothers (group 4) received a reduced dose of vaccine (2.5 micrograms) on three occasions as well as HBIG at birth. As compared with 78.4% of the control group (infants whose parents refused vaccination) who became chronic HBV carriers at the age of 14 months, the protective efficacy rate of vaccination was 75.3% in group 1,85.5% in group 2,89.7% in group 3, and 87.2% in group 4. HBV vaccine (5 micrograms) was also given to infants born to HBsAg-positive, HBeAg-negative mothers on four on four occasions. The antibody response to HBsAg in vaccine recipients was 12% after the first dose, 44% after the second dose, and 75% and 100% at six months and 1.5 years of age, respectively.

Adult↗